Hypertension, impaired metabolism of insulin, overweight, and changes in lipids profiles in patients with SUD under MMT can result in the risk of drug‐related mortality, metabolic abnormalities, infectious complications, pulmonary diseases, and diabetes (Cousins et al., 2011; Maruyama et al., 2013; Vallecillo et al., 2018). This evidence concerns the gene INS and diabetes mellitus.